p53 Aberrations do not predict individual to response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV

British Journal of Haematology

Volumn 129, Issue 1, 2005, Pages 53-59

  Valgañón, Mikel ^a   Giraldo, Pilar ^b   Agirre, Xabier ^c   Larráyoz, María J ^a   Rubio Martinez, Araceli ^b   Rubio Felix, Daniel ^b   Calasanz, Maria J ^a   Odero, María D ^a,c  

^a UNIVERSITY OF NAVARRA   (Spain)

^b FEHHA   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Chronic lymphocytic leukaemia; Fludarabine; Methylation; p53

Indexed keywords

FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ARTICLE; B CELL LEUKEMIA; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; METHYLATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOSOME ABERRATIONS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GENES, P53; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME; VIDARABINE;

EID: 17144376009     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05405.x     Document Type: Article

References (41)

1. Agirre, X., Vizmanos, J.L., Calasanz, M.J., Garcia-Delgado, M., Larrayoz, M.J. & Novo, F.J. (2003a) Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene, 22, 1070-1072.
2. Agirre, X., Novo, F.J., Calasanz, M.J., Larrayoz, M.J., Lahortiga, I., Valganon, M., Garcia-Delgado, M. & Vizmanos, J.L. (2003b) TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Molecular Carcinogenesis, 38, 201-208.
3. Barnabas, N., Shurafa, M., Van Dyke, D.L., Wolman, S.R., Clark, D. & Worsham, M.J. (2001) Significance of p53 mutations in patients with chronic lymphocytic leukemia: a sequential study of 30 patients. Cancer, 91, 285-293.
4. Baur, A.S., Shaw, P., Burri, N., Delacretaz, F., Bosman, F.T. & Chaubert, P. (1999) Frequent methylation silencing of p15 (INK4b) (MTS2) and p16 (INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood, 94, 1773-1781.
5. Campbell, M.J., Zelenetz, A.D., Levy, S. & Levy, R. (1992) Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Molecular Immunology, 29, 193-203.
6. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
7. Cuneo, A., Bigoni, R., Rigolin, G.M., Roberti, M.G., Bardi, A., Cavazzini, F., Milani, R., Minotto, C., Tieghi, A., Della Porta, M., Agostini, P., Tammiso, E., Negrini, M. & Castoldi, G. (2002) Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders. Clinicobiological significance. Haematologica, 87, 44-51.
8. Damle, R.N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A., Allen, S.L., Buchbinder, A., Budman, D., Dittmar, K., Kolitz, J., Lichtman, S.M., Schulman, P., Vinciguerra, V.P., Rai, K.R., Ferrarini, M. & Chiorazzi, N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 94, 1840-1847.
9. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J. & Stilgenbauer, S. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
10. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A., Bullinger, L., Dohner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1910-1916.
11. Esteller, M., Corn, P.G., Baylin, S.B. & Herman, J.G. (2001) A gene hypermethylation profile of human cancer. Cancer Research, 61, 3225-3229.
12. Fenaux, P., Preudhomme, C., Lai, J.L., Quiquandon, I., Jonveaux, P., Vanrumbeke, M., Sartiaux, C., Morel, P., Loucheux-Lefebvre, M.H. & Bauters, F. (1992) Mutations of the p53 gene in B-cell chronic lymphocytic leukemia: a report on 39 cases with cytogenetic analysis. Leukemia, 6, 246-250.
13. Gaidano, G., Ballerini, P., Gong, J.Z., Inghirami, G., Neri, A., Newcomb, E.W., Magrath, I.T., Knowles, D.M. & Dalla-Favera, R. (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 88, 5413-5417.
14. Gaidano, G., Newcomb, E.W., Gong, J.Z., Tassi, V., Neri, A., Cortelezzi, A., Calori, R., Baldini, L. & Dalla-Favera, R. (1994) Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. American Journal of Pathology, 144, 1312-1319.
15. Hamblin, T.J., Davis, Z., Gardiner, A., Oscier, D.G. & Stevenson, F.K. (1999) Unmutated Ig V (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 94, 1848-1854.
16. Keating, M.J., O'Brien, S., Lerner, S., Koller, C., Beran, M., Robertson, L.E., Freireich, E.J., Estey, E. & Kantarjian, H. (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood, 92, 1165-1171.
17. Krober, A., Seiler, T., Benner, A., Bullinger, L., Bruckle, E., Lichter, P., Dohner, H. & Stilgenbauer, S. (2002) V (H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100, 1410-1416.
18. Lane, D. (2004) p53 from pathway to therapy. Carcinogenesis, 25, 1077-1081.
19. Leporrier, M. (2004) Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Hematology Journal, 5(suppl. 1), S10-S19.
20. Leporrier, M., Chevret, S., Cazin, B., Boudjerra, N., Feugier, P., Desablens, B., Rapp, M.J., Jaubert, J., Autrand, C., Divine, M., Dreyfus, B., Maloum, K., Travade, P., Dighiero, G., Binet, J.L. & Chastang, C. (2001) Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood, 98, 2319-2325.
21. Lin, K., Sherrington, P.D., Dennis, M., Matrai, Z., Cawley, J.C. & Pettitt, A.R. (2002) Relationship between p53 dysfunction, CD38 expression, and IgV (H) mutation in chronic lymphocytic leukemia. Blood, 100, 1404-1409.
22. Mass, M.J. & Wang, L. (1997) Arsenic alters cytosine methylation patterns of the promoter of the tumor suppressor gene p53 in human lung cells: a model for a mechanism of carcinogenesis. Mutation Research, 386, 263-277.
23. Montserrat, E. (2004) Treatment options in chronic lymphocytic leukemia. Hematology Journal, 5(suppl. 1), S2-S9.
24. O'Brien, S.M., Kantarjian, H.M., Cortes, J., Beran, M., Koller, C.A., Giles, F.J., Lerner, S. & Keating, M. (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19, 1414-1420.
25. Odero, M.D., Carlson, K., Calasanz, M.J., Lahortiga, I., Chinwalla, V. & Rowley, J.D. (2001) Identification of new translocations involving ETV6 in hematologic malignancies by fluorescence in situ hybridization and spectral karyotyping. Genes, Chromosomes and Cancer, 31, 134-142.
26. Oscier, D.G., Gardiner, A.C., Mould, S.J., Glide, S., Davis, Z.A., Ibbotson, R.E., Corcoran, M.M., Chapman, R.M., Thomas, P.W., Copplestone, J.A., Orchard, J.A. & Hamblin, T.J. (2002) Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100, 1177-1184.
27. Pettitt, A.R., Sherrington, P.D. & Cawley, J.C. (1999a) The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. British Journal of Haematology, 106, 1049-1051.
28. Pettitt, A.R., Clarke, A.R., Cawley, J.C. & Griffiths, S.D. (1999b) Purine analogues kill resting lymphocytes by p53-dependent and -independent mechanisms. British Journal of Haematology, 105, 986-988.
29. Pettitt, A.R., Sherrington, P.D., Stewart, G., Cawley, J.C., Taylor, A.M. & Stankovic, T. (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood, 98, 814-822.
30. Pogribny, I.P. & James, S.J. (2002) Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation. Cancer Letters, 176, 169-174.
31. Pogribny, I.P., Pogribna, M., Christman, J.K. & James, S.J. (2000) Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis. Cancer Research, 60, 588-594.
32. Rai, K.R., Peterson, B.L., Appelbaum, F.R., Kolitz, J., Elias, L., Shepherd, L., Hines, J., Threatte, G.A., Larson, R.A., Cheson, B.D. & Schiffer, C.A. (2000) Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. New England Journal of Medicine, 343, 1750-1757.
33. Rossi, D., Capello, D., Gloghini, A., Franceschetti, S., Paulli, M., Bhatia, K., Saglio, G., Vitolo, U., Piled, S.A., Esteller, M., Carbone, A. & Gaidano, G. (2004) Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica, 89, 154-164.
34. el Rouby, S., Thomas, A., Costin, D., Rosenberg, C.R., Potmesil, M., Silber, R. & Newcomb, E.W. (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452-3459.
35. Schroeder, M. & Mass, M.J. (1997) CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. Biochemical and Biophysical Research Communications, 235, 403-406.
36. Shanafelt, T.D., Geyer, S.M. & Kay, N.E. (2004) Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood, 103, 1202-1210.
37. Stilgenbauer, S., Bullinger, L., Lichter, P. & Dohner, H. (2002) Genetics of chronic lymphocytic leukemia: genomic aberrations and V (H) gene mutation status in pathogenesis and clinical course. Leukemia, 16, 993-1007.
38. Swinscow, T.D.V. (1997) Statistics at Square One. BMJ Publishing Group, London.
39. Venkatachalam, S., Shi, Y.P., Jones, S.N., Vogel, H., Bradley, A., Pinkel, D. & Donehower, L.A. (1998) Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO Journal, 17, 4657-4667.
40. Zhu, Y., Loukola, A., Monni, O., Kuokkanen, K., Franssila, K., Elonen, E., Vilpo, J., Joensuu, H., Kere, J., Aaltonen, L. & Knuutila, S. (2001) Ppp2r1b gene in chronic lymphocytic leukemias and mantle cell lymphomas. Leukemia and Lymphoma, 41, 177-183.
41. Zojer, N., Konigsberg, R., Ackermann, J., Fritz, E., Dallinger, S., Kromer, E., Kaufmann, H., Riedl, L., Gisslinger, H., Schreiber, S., Heinz, R., Ludwig, H., Huber, H. & Drach, J. (2000) Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Multicenter Investigation of Bone Marrow Transplantation for Sickle Cell Disease. Blood, 95, 1925-1930.